oncolytic adenovirus expressing human interferon alpha

An experimental **oncolytic virus therapy** consisting of a conditionally replicative adenovirus genetically engineered to express **human interferon alpha** within infected tumor cells. In preclinical work, including pancreatic cancer and esophageal adenocarcinoma models, the vector was designed to replicate selectively in malignant cells, in some constructs using a **cyclooxygenase-2 promoter** and insertion of the **IFN-alpha transgene in the adenoviral E3 region**. The intended therapeutic effect combines direct tumor cell lysis from adenoviral replication with local cytokine-mediated antitumor and immunomodulatory activity from interferon alpha expression, aiming to improve efficacy while reducing the systemic toxicity associated with exogenous interferon administration. Development appears to have been led primarily by academic investigators, including groups associated with the University of Minnesota, rather than a clearly identified commercial sponsor.

Other names

oncolytic adenovirus expressing interferon alphainterferon alpha-expressing oncolytic adenovirusconditionally replicative adenovirus expressing human interferon alphaCox2-controlled interferon alpha-expressing adenovirusCox-2-controlled interferon alpha-expressing adenovirusCox 2-controlled interferon alpha-expressing adenovirus